Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • Tapentadol.svg
    Biotech,  China,  Court Cases,  Courts,  Pharma,  Supreme People's Court

    Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

    July 14, 2020

    This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and inventor of the opioid painkiller Pentadol[1]. Grünenthal has a Chinese patent (ZL 200580021661.1) with claims directed towards a new crystalline form of particular phenol hydrochloride (“tapentastat hydrochloride” and “Form A” in claim 1), processes for preparing tapentastat hydrochloride (claim 3), and processes for preparing Form A (claims 16 and 23). Form A is made by…

    Read More
    eagleip 2 Comments

    Related Posts

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018

    No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

    November 23, 2018

    Diagnostic Claims in China

    January 9, 2020
  • China,  Court Cases,  Courts,  Top 50 Representative Cases

    Stealing Trade Secrets: How the Chinese Court Criminally Sentences Employees that Steal Trade Secrets – 2019 China’s Top 50 Representative IP Cases

    June 11, 2020

    The theft of trade secrets has always been a deep concern of foreign companies thinking of doing business in China, whether it be sharing protocols with a manufacturing partner, providing technology details to a potential investor, or sharing results from an R&D collaboration. How can businesses ensure that employees do not steal secrets and share them with others, such as competitors? If such stealing occurs, what are the consequences? Recently, China chose to highlight this topic in one of its Top 50 Representative IP Cases. Hua Xing v. Lin, Ye, and Zheng (2018 粤13刑终361号) emphasizes the criminal nature of violating and misappropriating trade secrets and the possible consequences for those…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • China,  Courts,  Updates and Changes

    Finally a unified “Court of Appeal” for technology IP in China

    January 22, 2019

    On October 26, 2018, China’s Supreme People’s Court (“SPC”) received approval to establish a specialized intellectual property court within the SPC to handle appeal cases involving technology-related IP for both civil (e.g., patent infringement) and administrative (e.g., patent invalidity) judgments. Technology-related IP includes invention patents, utility models, new plant species, IC design, trade secret, software, and anti-trust cases. [1] On December 28, 2018, the SPC announced the opening of this new SPC IP Court on January 1, 2019, and laid out some details surrounding how things would work [2]. We have summarized some of the details below. The SPC IP Court is based in Beijing and its judgments, rulings, mediations,…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
Newer Posts 

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard
  • May 22, 2026 Breaking: China Released Drug Trial Data Protection Implementation Measures
  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

Categories

Archives

  • June 2026
  • May 2026
  • April 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard
  • May 22, 2026 Breaking: China Released Drug Trial Data Protection Implementation Measures
  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
  • Jan 07, 2026 Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data
  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China
  • Oct 21, 2025 From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
© 2026 Eagle IP Limited
Savona Theme by Optima Themes